<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778413</url>
  </required_header>
  <id_info>
    <org_study_id>A-TRI-WEEK</org_study_id>
    <nct_id>NCT01778413</nct_id>
  </id_info>
  <brief_title>Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine</brief_title>
  <acronym>A-TRI-WEEK</acronym>
  <official_title>Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Cruceta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to determine the feasibility of maintaining virologic suppression on
      standard plasma viral load by dose reduction of ATRIPLA ®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to determine the feasibility of maintaining virologic
      suppression on standard plasma viral load (limit of detection 37 copies / mL) of a dose
      reduction strategy of ATRIPLA ® once a day to three tablets per week in patients infected
      with HIV-1 with sustained suppression of plasma viral load standard for more than two years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who continue with a standard plasma viral load (&lt;37 copies / mL) at 24 weeks by intention to treat analysis.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with ultrasensitive viral load (&lt;1 copy / mL) after 24 weeks.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to 24 weeks in the viral reservoir in peripheral blood mononuclear cells</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Changes from baseline to 24 weeks in the production of TRECs, the immunological profile of activation (CD38 and HLA-DR) and senescence (CD57 and CD28) in CD4 and CD8 lineages in the proportions of naive T cells effector and memory (CCR7 and CD45RA), and changes in the levels of apoptosis in vitro by staining with annexin V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma levels of efavirenz.</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sleep quality (Pittsburgh Sleep Quality Index).</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Safety (report adverse events, serious adverse events and treatment discontinuation due to adverse events)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma levels of vitamin D.</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lipid profile.</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in estimated glomerular filtration rate.</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>ATRIPLA three times a week.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atripla (600 mg/200 mg/245 mg) three times a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATRIPLA one time a day.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atripla (600 mg/200 mg/245 mg) one time a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATRIPLA</intervention_name>
    <arm_group_label>ATRIPLA three times a week.</arm_group_label>
    <arm_group_label>ATRIPLA one time a day.</arm_group_label>
    <other_name>efavirenz/emtricitabine/tenofovir disoproxil fumarate 600 mg/200</other_name>
    <other_name>mg/245 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (≥ 18 years)

          -  HIV-1 infection, clinical stability, and treatment with ATRIPLA ® for the past two
             years.

          -  Standard plasma viral load below the limit of detection for at least 2 years.

          -  CD4 count above 350/mm3 at the time of the consideration for the study.

          -  Negative pregnancy test in women of childbearing age, and commitment acceptable
             contraceptive use for at least 2 weeks before day 1 and until at least 6 months after
             the last dose of study drug.

          -  Patients should be given written informed consent

          -  In the opinion of the investigator, be able to follow the design of the protocol
             visits

        Exclusion Criteria:

          -  Patients who have experienced virologic failure prior to any antiretroviral regimen

          -  Evidence of previous mutations versus efavirenz, tenofovir and emtricitabine

          -  Use of any other chronic treatment plus ATRIPLA has been introduced in the 6 months
             prior to entry of the patient in the study

          -  Any contraindication to study drug

          -  Any condition not ensure proper adherence to the study at the discretion of the
             attending physician of the patient

          -  Uncontrolled preexisting psychiatric illness

          -  Any current sign of alcoholism or other drug use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esteban Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Project manager</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

